Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epinephrine Nasal Spray in Paediatric Allergy Patients
NCT07891780Phase 2Not yet recruiting
- Sponsor
- Hikma Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of epinephrine nasal spray in anaphylaxis, type I hypersensitivity, sponsored by Hikma Pharmaceuticals. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
epinephrine nasal spray
03
Conditions
anaphylaxistype I hypersensitivity
Beyond the preview
Go deeper on NCT07891780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891780.